Pregabalin Alternatives Compared
Pregabalin | Aimovig | Emgality |
|
---|
Pregabalin | Aimovig (erenumab) | Emgality (galcanezumab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Pregabalin is used in the treatment of nerve pain and also to prevent seizures. Drowsiness or dizziness are common side effects, and it has the potential to be misused. Prescribed for Neuropathic... View more |
Prescription only
Aimovig is a prescription medicine that can be self-injected under the skin once a month to prevent migraine headaches in adults. Injection site reactions and constipation are the most common side... View more |
Prescription only
Emgality is an injectable medication that can be self-administered subcutaneously (under the skin) once monthly for the prevention of migraine in adults or during a cluster headache period when used... View more |
Related suggestions Migraine Prevention (Migraine Prophylaxis)
|
|||||||||||||||||||||||
More about Pregabalin | More about Aimovig (erenumab) | More about Emgality (galcanezumab) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Pregabalin has an average rating of 6.8 out of 10 from a total of 1635 ratings on drugclasses.com. 58% of reviewers reported a positive effect, while 24% reported a negative effect. |
Aimovig has an average rating of 5.1 out of 10 from a total of 622 ratings on drugclasses.com. 37% of reviewers reported a positive effect, while 44% reported a negative effect. |
Emgality has an average rating of 5.1 out of 10 from a total of 470 ratings on drugclasses.com. 36% of reviewers reported a positive effect, while 46% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: pregabalin side effects in more detail. |
See also: Aimovig side effects in more detail. |
See also: Emgality side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all pregabalin prices |
View all Aimovig prices |
View all Emgality prices |
||||||||||||||||||||||||
Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Lyrica, Lyrica CR |
N/A |
N/A |
||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
6.3 hours |
672 hours |
648 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Some potential for abuse
Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 284 drugs are known to interact with pregabalin:
|
A total of 2 drugs are known to interact with Aimovig:
|
A total of 2 drugs are known to interact with Emgality:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
|
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.